Fibroblast growth factor 2 as a new approach to fighting fear

JAMA Psychiatry

Volumn 72, Issue 10, 2015, Pages 959-960

  Graham, Bronwyn M ^a   Richardson, Rick ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CYCLOSERINE; FIBROBLAST GROWTH FACTOR 2; SEROTONIN UPTAKE INHIBITOR; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; FIBROBLAST GROWTH FACTOR;

ANXIETY DISORDER; CLINICAL PSYCHOLOGY; DEPRESSION; DRUG EFFICACY; EXPOSURE THERAPY; FEAR; GENE EXPRESSION; HIPPOCAMPUS; HUMAN; LEARNING; MAJOR DEPRESSION; MEMORY CONSOLIDATION; MENTAL DISEASE; NEUROSCIENCE; NONHUMAN; NOTE; PSYCHIATRY; PSYCHOTHERAPY; SUICIDE; TRANQUILIZING ACTIVITY; TREATMENT OUTCOME; ANIMAL; BRAIN; GENETICS; MOOD DISORDER; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN; FIBROBLAST GROWTH FACTORS; HUMANS; MOOD DISORDERS; NEUROTRANSMITTER AGENTS;

EID: 84943571292     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2015.1187     Document Type: Note

References (7)

1. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72(4):334-341.
2. Holmes EA, Craske MG, Graybiel AM. Psychological treatments: a call for mental-health science. Nature. 2014;511(7509):287-289.
3. Singewald N, Schmuckermair C, Whittle N, Holmes A, Ressler KJ. Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacol Ther. 2015;149:150-190.
4. Turner CA, Watson SJ, Akil H. The fibroblast growth factor family: neuromodulation of affective behavior. Neuron. 2012;76(1):160-174.
5. Graham BM, Richardson R. Acute systemic fibroblast growth factor-2 enhances long-term extinction of fear and reduces reinstatement in rats. Neuropsychopharmacology. 2009;34(7):1875-1882.
6. Graham BM, Richardson R. Intraamygdala infusion of fibroblast growth factor 2 enhances extinction and reduces renewal and reinstatement in adult rats. J Neurosci. 2011;31(40):14151-14157.
7. Lederman RJ, Mendelsohn FO, Anderson RD, et al; TRAFFIC Investigators. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC Study): a randomised trial. Lancet. 2002;359 (9323):2053-2058.